Related Experiment Video
Updated: Aug 20, 2026
Murine Model of Intestinal Ischemia-reperfusion Injury
Published on: May 11, 2016
[Protective effects of modified recombinant human acidic fibroblast growth factor on small intestine after
Tong-zhu Sun1, Xiao-bing Fu, Wei Chen
1Key Laboratory of Wound Repair, 304th Clinical Department of General Hospital of PLA, Beijing 100037 China.
Objective:
To explore the protective effect of modified recombinant human acidic fibroblast growth factor (rhaFGF) on small intestinal after ischemia/reperfusion (I/R) injury in rats.
Methods:
The clamp on the superior mesenteric artery (SMA) was removed after clamping it for 45 minutes to replicate I/R injury of the intestine in the rat. Rats were then divided randomly into sham operation group, normal saline treatment group and rhaFGF treatment group, in which the rats of the normal saline treatment group were injected 0.1 ml of normal saline and that of the rhaFGF group were given 4 microg of rhaFGF immediately after reperfusion. The content of D-lactate in the plasma was determined and the changes in intestinal pathology were observed. At the same time, the rates of apoptosis of intestinal epithelial cells were assessed 2, 6, 12 and 24 hours after I/R, and compared to the sham operation group.
Results:
The plasma content of D-lactate in the saline treatment group at 6 hours after I/R reached (0.34+/-0.09) mg/L and was significantly higher than that in the rhaFGF treatment group((0.23+/-0.07)mg/L, P<0.05). It was shown histologically that the intestinal structures were damaged more seriously in saline treatment group than in rhaFGF group. The apoptosis rates in the saline treatment group and rhaFGF group were elevated significantly, peaking at 12 hours after I/R injury((62.8+/-1.7)% in saline group and (42.5+/-2.6)% in rhaFGF treatment group), then the rate began to fall. There was statistically significant difference between the two groups at 12 hours after I/R injury.
Conclusion:
rhaFGF can reduce content of D-lactate in the plasma and rate of apoptosis of epithelial cells in the intestine after I/R injury, thus it seems to afford a protective effect on the small intestine after I/R injury in rats.
Insights
Modified recombinant human acidic fibroblast growth factor (rhaFGF) protects the rat small intestine from ischemia/reperfusion (I/R) injury. This study shows rhaFGF reduces plasma D-lactate and epithelial cell apoptosis following I/R.
Area of Science:
- Gastroenterology
- Regenerative Medicine
- Cell Biology
Context:
- Intestinal ischemia/reperfusion (I/R) injury is a critical condition leading to significant small bowel damage.
- Current therapeutic strategies for I/R injury have limitations, necessitating novel protective agents.
- Fibroblast growth factors (FGFs) are implicated in tissue repair and regeneration.
Purpose:
- To investigate the protective efficacy of modified recombinant human acidic fibroblast growth factor (rhaFGF) against I/R-induced small intestinal injury in a rat model.
- To evaluate the impact of rhaFGF on key biomarkers of injury, including plasma D-lactate levels and intestinal epithelial cell apoptosis.
Summary:
- Rats subjected to superior mesenteric artery occlusion for 45 minutes developed I/R injury.
- Treatment with rhaFGF post-reperfusion significantly reduced plasma D-lactate levels compared to saline controls.
- Histological analysis revealed less severe intestinal damage in the rhaFGF group, with significantly lower rates of epithelial cell apoptosis at 12 hours post-I/R.
Impact:
- Demonstrates the therapeutic potential of rhaFGF in mitigating I/R-induced small intestinal injury.
- Suggests rhaFGF as a promising candidate for further preclinical and clinical development for treating intestinal I/R injury.
- Provides insights into the molecular mechanisms underlying FGF-mediated protection in ischemic conditions.
